Pfizer's stock (PFE) plummeted 5.11% during intraday trading on Tuesday after the company issued a weaker-than-expected profit forecast for 2026, disappointing investors.
The drugmaker projected adjusted earnings per share of $2.80 to $3 for 2026, below analysts' average estimate of $3.05. Revenue is expected to range between $59.5 billion and $62.5 billion, also missing consensus estimates. The guidance reflects a $1.5 billion decline in COVID-19 product sales and another $1.5 billion hit from the loss of exclusivity on older drugs.
Pfizer also revised its 2025 revenue forecast to approximately $62 billion, down from its earlier range of $61 billion to $64 billion. The company is working to cut costs and streamline its business, but the weak outlook overshadowed these efforts.
Comments